


## Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently amended) A compound of formula I:




or a pharmaceutically acceptable acid addition salt thereof, where;

~~R¹ is C<sub>4</sub>-C<sub>6</sub>-alkyl, substituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, substituted C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, substituted C<sub>3</sub>-C<sub>7</sub>-cycloalkyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, phenyl substituted with one to three halo substituents, substituted phenyl, heterocycle,~~

~~or substituted heterocycle;~~

~~R² is hydrogen, or C<sub>1</sub>-C<sub>3</sub>-alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, or a group of formula II~~



~~\_\_\_\_\_~~  
~~\_\_\_\_\_~~ H;

~~R³ is hydrogen or methyl C<sub>1</sub>-C<sub>3</sub>-alkyl;~~

~~R⁴ is hydrogen, halo, or C<sub>1</sub>-C<sub>3</sub>-alkyl; and~~


~~R⁵ is hydrogen or C<sub>1</sub>-C<sub>3</sub>-alkyl;~~

~~R⁶ is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl; and~~

~~n is an integer from 1 to 6 inclusively.~~

2. – 12. (Canceled)


13. (Withdrawn, currently amended) A method for the treatment or prevention of migraine in a mammal comprising administering to a mammal in need of such treatment or prevention an effective amount of a compound of formula I:



or a pharmaceutically acceptable acid addition salt thereof, where;

~~R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub>-alkyl, substituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, substituted C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, substituted C<sub>3</sub>-C<sub>7</sub>-cycloalkyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, phenyl, substituted with one to three halo substituents, phenyl, heterocycle, or substituted heterocycle;~~

~~R<sup>2</sup> is hydrogen, or C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-C<sub>1</sub>-C<sub>3</sub>-alkyl, or a group of formula II~~



~~R<sup>3</sup> is hydrogen or methyl C<sub>1</sub>-C<sub>3</sub>-alkyl;~~

~~R<sup>4</sup> is hydrogen, halo, or C<sub>1</sub>-C<sub>3</sub>-alkyl; and~~

~~R<sup>5</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub>-alkyl;~~

~~R<sup>6</sup> is hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl; and~~


~~n is an integer from 1 to 16 inclusively.~~

14. (Withdrawn) The method according to Claim 13 wherein the mammal is a human.

15-26. (Canceled)


27. (Withdrawn) A process for preparing a 2-halo-6-(piperidin-4-carbonyl)pyridine

compound of formula III



where X is bromo or chloro;

$R^8$  is an amino protecting group,  $C_1$ - $C_3$  alkyl,  $C_3$ - $C_6$  cycloalkyl- $C_1$ - $C_3$  alkyl, or a group of formula II




$R^6$  is hydrogen or  $C_1$ - $C_6$  alkyl; and

n is an integer from 1 to 6 inclusively;


comprising

- 1) reacting a 2,6-dihalopyridine selected from 2,6-dibromopyridine and 2,6-dichloropyridine, with n-butyl lithium to form 2-halo-6-lithium-pyridine, and then
- 2) reacting the 2-halo-6-lithium-pyridine with a substituted aminocarbonylpiperidine compound of formula IV




wherein  $R^9$  and  $R^{10}$  are each methyl, or  $R^9$  and  $R^{10}$ , together with the nitrogen to which they are attached, combine to form azetidiny, pyrrolidinyl, or piperidinyl.

28. (Withdrawn) The process of Claim 27 wherein X is bromo and the 2,6-dihalopyridine is 2,6-dibromopyridine.
29. (Withdrawn) The process of Claim 27 wherein  $R^9$  and  $R^{10}$  are each methyl.
30. (Withdrawn) The process of Claim 27 wherein  $R^9$  and  $R^{10}$ , together with the nitrogen to which they are attached, combine to form pyrrolidinyl.
31. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is methyl-*t*-butylether.
32. (Withdrawn) The process of Claim 27 wherein the solvent for step 2) is toluene.
33. (Withdrawn) A method for preparing a 2-bromo-6-(piperidin-4-carbonyl)pyridine compound of formula III



wherein  $R^7$  is  $C_1$ - $C_3$  n-alkyl, or an amino protecting group;

comprising reacting 2,6-dibromopyridine with n-butyl lithium to form 2-bromo-6-lithium-pyridine, and then reacting the 2-bromo-6-lithium-pyridine with a 4-(N,N'-dimethylamino)carbonyl piperidine compound of formula IV



- in a methyl-*tert*-butyl ether solvent.
34. (Withdrawn) The process of Claim 28 wherein R<sup>9</sup> and R<sup>10</sup> are each methyl.
  35. (Withdrawn) The process of Claim 28 wherein R<sup>9</sup> and R<sup>10</sup>, together with the nitrogen to which they are attached, combine to form pyrrolidinyl.
  36. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is methyl-*t*-butylether.
  37. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is methyl-*t*-butylether.
  38. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is methyl-*t*-butylether.
  39. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is methyl-*t*-butylether
  40. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is methyl-*t*-butylether.
  41. (Withdrawn) The process of Claim 28 wherein the solvent for step 2) is toluene.
  42. (Withdrawn) The process of Claim 29 wherein the solvent for step 2) is toluene.
  43. (Withdrawn) The process of Claim 30 wherein the solvent for step 2) is toluene.
  44. (Withdrawn) The process of Claim 34 wherein the solvent for step 2) is toluene.
  45. (Withdrawn) The process of Claim 35 wherein the solvent for step 2) is toluene.

46. - 54. (Canceled).

55. (Currently amended) A pharmaceutical formulation comprising a compound of Claim 1 ~~any one of Claims 1-4, 6, 7, 4[[6]]9-54~~ and a pharmaceutical carrier, diluent, or excipient.

56. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide or a pharmaceutically acceptable acid addition salt thereof.

57. (Previously Presented) The compound 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hemisuccinate salt.

58. (Previously Presented) The compound 2, 4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-benzamide hydrochloride salt.

59. (New) A pharmaceutical formulation comprising a compound of Claim 56 and a pharmaceutical carrier, diluent, or excipient.

60. (New) A pharmaceutical formulation comprising a compound of Claim 57 and a pharmaceutical carrier, diluent, or excipient.

61. (New) A pharmaceutical formulation comprising a compound of Claim 58 and a pharmaceutical carrier, diluent, or excipient.